Australien - Englisch - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - interferon beta-1a, quantity: 60 microgram/ml - injection, solution - excipient ingredients: arginine hydrochloride; polysorbate 20; sodium acetate; water for injections; glacial acetic acid - avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis (ms). avonex is indicated in patients who have experienced a single demyelinating event and are at risk of developing clinically definite ms based on the presence of brain mri abnormalities characteristic of ms. avonex 60 mcg is indicated for the treatment of secondary progressive ms in patients in whom relapse is still a feature of disease. avonex 60 mcg should not be initiated in patients with secondary progressive ms who have not experienced relapse in the previous 12 months.

Israel - Englisch - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 88 mcg/ml - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiplbe sclerosis has not been established.rebif is indicated for the treatment of patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

Israel - Englisch - Ministry of Health

medison pharma ltd - interferon beta 1a - solution for injection - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

Europäische Union - Englisch - EMA (European Medicines Agency)

biogen netherlands b.v. - peginterferon beta-1a - multiple sclerosis - immunostimulants, - treatment of relapsing remitting multiple sclerosis in adult patients.

Israel - Englisch - Ministry of Health

medison pharma ltd - peginterferon beta 1a - solution for injection - peginterferon beta 1a 125 mcg / 0.5 ml - peginterferon beta-1a - plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis